Data Silicon Awards: Kalray Wins Gold Innovation Award, Public Award and Bronze Grand Prize With Its New Generation DPU Processor
Kalray (Euronext Growth Paris : ALKAL), a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from Cloud to Edge, has won several awards, including the Gold Innovation Award, the Public Award and the Bronze Award at the Data Silicon Awards, held on October 20, 2022, in Paris. Organized as part of the Silicon Day Data, the Silicon Data Awards recognize the best data projects, solutions and innovations in the IT and tech world. These awards once again recognize Kalray’s unique technology, which also won an award at the Flash Memory Summit last August.
Kalray's DPU: A New Type of Processor in the Spotlight
"We are delighted to have won these awards, it is a recognition of our innovative technology but also of the whole project delivered by Kalray to revolutionize the way data will be processed and managed in the future. DPU processors are going to play a crucial role in tomorrow's industries and are attracting increasing interest. Processors designed for yesterday's needs, such as CPUs and GPUs, cannot always efficiently analyze the huge amounts of data generated by today's applications. Kalray's teams have developed a technology that can exploit the full potential of a world that now relies on massive and disparate data to be processed as quickly as possible: the MPPA® DPU", explains Eric Baissus, Kalray CEO.
With its patented 80-core architecture, Kalray's DPU processor manages multiple data streams in parallel and without bottlenecks. It enables applications exploiting massive amounts of data to be more intelligent, efficient and energy-saving. Kalray’s DPU is a low-power, high-performance programmable processor dedicated to data-intensive applications for fast-growing markets such as the data center, AI, edge computing, 5G, automotive ...
“Innovation has been at the heart of VMware's DNA for more than twenty years. Through these Silicon Data Awards, I am delighted to see the dynamism of our ecosystem and the quality of the projects presented. The prizes awarded to Kalray recognize an innovative and unique technology through its DPU processor, and demonstrate the ability of our ecosystem to innovate in both hardware and software for more efficient data processing and management,” comments Marc Dollois, Vice-President and General Manager of VMware France and member of the Silicon Data Awards jury.
Kalray, the Only Player in Europe to Offer a DPU Processor
A spin-off from CEA Leti, one of the most advanced laboratories in the field of semiconductors, Kalray has developed a technological lead that enables it to offer a highly competitive alternative to the mainly American and Chinese players, and is the only player in Europe to offer this type of processor - an asset for the technological sovereignty of France and Europe.
The company has already been selected by Cloud customers such as Clever Cloud in France and is collaborating with Dell Technologies, the world leader in storage, through a strategic partnership. The company is also involved in a number of European collaborative projects such as the European Initiative Processor (EPI), PIRANA and 5G-OPERA projects around 5G. In a recent joint press release, Kalray, 2CRSi, Clever Cloud and Vates also announced their collaboration to equip data centers with innovative and sovereign hardware: a project to develop solutions for Cloud and Edge data center infrastructures around Kalray's DPU processor and its partners' innovative virtualization and software technologies.
Become a Major Player in Intelligent Data Processing and Management
Kalray aims to become a global leader in intelligent processing and data management. To this end, the company acquired Arcapix Holdings Ltd, a UK-based software company specializing in data storage and management solutions for computationally intensive applications, in March 2022.
"Although the semiconductor industry is dominated by a handful of players the emergence of new uses and new technologies is reshuffling the deck. With each technological breakthrough, we have seen new players emerge who have subsequently become leaders in their field because they have been able to provide a technological response to new needs that existing solutions could not fully satisfy. I am convinced that Kalray's technology can help us do just that.
With the acquisition of Arcapix, we can now also offer highly complementary software solutions to meet the evolving needs in the world of data-intensive storage and processing, and accelerate the time-to-market of our technology. This acquisition strengthens our position in the storage market and is perfectly in line with Kalray's development strategy and ambition, complementing our products, teams, expertise and markets, and eventually making Kalray a world leader in intelligent processing and data management", concludes Eric Baissus.
ABOUT KALRAY
Kalray (Euronext Growth Paris - ALKAL) is a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products and solutions to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Its offerings include its unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as its leading-edge software-defined storage and data management solutions. Implemented individually or in combination, Kalray's high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance. Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005788/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
+ 33 1 53 67 36 72
PRESS CONTACTS
Sylvie DAM
communication@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new